Andrea Ellis Sells 64,921 Shares of BridgeBio Pharma (NASDAQ:BBIO) Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Andrea Ellis sold 64,921 shares of the stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $64.87, for a total value of $4,211,425.27. Following the sale, the director owned 18,589 shares of the company’s stock, valued at $1,205,868.43. This trade represents a 77.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link.

BridgeBio Pharma Stock Down 1.2%

Shares of NASDAQ BBIO opened at $65.36 on Friday. The stock’s fifty day simple moving average is $73.64 and its 200 day simple moving average is $65.34. The stock has a market capitalization of $12.67 billion, a price-to-earnings ratio of -17.29 and a beta of 1.13. BridgeBio Pharma, Inc. has a 52-week low of $28.33 and a 52-week high of $84.94.

BridgeBio Pharma (NASDAQ:BBIO) last announced its earnings results on Tuesday, February 24th. The company reported ($1.00) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.25). The firm had revenue of $154.18 million during the quarter, compared to analyst estimates of $150.71 million. The firm’s revenue was up 2521.2% compared to the same quarter last year. During the same period last year, the company posted ($1.40) earnings per share. As a group, analysts anticipate that BridgeBio Pharma, Inc. will post -3.67 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have recently weighed in on BBIO shares. Wells Fargo & Company lifted their target price on shares of BridgeBio Pharma from $88.00 to $98.00 and gave the stock an “overweight” rating in a research report on Friday, February 13th. TD Cowen restated a “buy” rating on shares of BridgeBio Pharma in a report on Monday, January 12th. Barclays initiated coverage on shares of BridgeBio Pharma in a research report on Wednesday, January 28th. They issued an “overweight” rating for the company. Leerink Partners lifted their price objective on shares of BridgeBio Pharma from $75.00 to $86.00 and gave the stock an “outperform” rating in a research report on Monday, December 15th. Finally, Morgan Stanley boosted their target price on shares of BridgeBio Pharma from $96.00 to $98.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Twenty-two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, BridgeBio Pharma currently has an average rating of “Moderate Buy” and a consensus target price of $82.50.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Invesco Ltd. boosted its stake in shares of BridgeBio Pharma by 23.0% during the 4th quarter. Invesco Ltd. now owns 4,831,305 shares of the company’s stock valued at $369,547,000 after buying an additional 902,648 shares during the period. Mackenzie Financial Corp increased its stake in shares of BridgeBio Pharma by 8.9% in the fourth quarter. Mackenzie Financial Corp now owns 54,495 shares of the company’s stock worth $4,105,000 after acquiring an additional 4,448 shares during the last quarter. XTX Topco Ltd increased its stake in shares of BridgeBio Pharma by 162.4% in the fourth quarter. XTX Topco Ltd now owns 13,169 shares of the company’s stock worth $1,007,000 after acquiring an additional 8,150 shares during the last quarter. VARCOV Co. purchased a new stake in shares of BridgeBio Pharma during the fourth quarter worth $340,000. Finally, Voloridge Investment Management LLC raised its holdings in shares of BridgeBio Pharma by 377.4% during the fourth quarter. Voloridge Investment Management LLC now owns 638,883 shares of the company’s stock worth $48,868,000 after acquiring an additional 505,051 shares in the last quarter. 99.85% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting BridgeBio Pharma

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Positive Phase 3 BBP-418 data in LGMD2I/R9 strengthens the clinical and revenue upside narrative for BridgeBio’s rare-disease pipeline; that result is being argued as expanding the company’s long-term bull case. Does Positive Phase 3 BBP-418 Data in LGMD2I/R9 Change The Bull Case For BridgeBio Pharma (BBIO)?
• Positive Sentiment: Truist raised its price target to $95 and kept a Buy rating, citing recent commercial traction (pre-announced Attruby sales) — a notable analyst endorsement that can support investor confidence and boost valuation expectations. Truist Raises Its Price Target on BridgeBio Pharma, Inc. (BBIO) to $95 and Maintains a Buy Rating
• Positive Sentiment: Consensus analyst sentiment remains constructive (MarketBeat/AmericanBankingNews report a “Moderate Buy” consensus and an $82.50 average target), suggesting broad Wall Street support despite recent volatility. BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Rating of “Moderate Buy” from Analysts
• Neutral Sentiment: Reported short-interest data in the feed is inconsistent/unclear (entries show 0 shares and NaN changes), so there’s no clear signal from short-sellers to explain today’s move.
• Negative Sentiment: Director Andrea Ellis sold 64,921 shares (~$4.21M) on March 4, cutting her stake by ~77.7% — insider selling can be interpreted negatively by the market even when for personal/liquidity reasons. BridgeBio Pharma (NASDAQ:BBIO) Director Sells $4,211,425.27 in Stock
• Negative Sentiment: Recent quarterly results showed an EPS miss (reported ($1.00) vs. consensus ($0.75)), reminding investors that BridgeBio is still delivering mixed near-term financials despite big revenue improvements year-over-year.

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.